Fatih M. Uckun, M.D., Ph.D Email and Phone Number
Fatih M. Uckun, M.D., Ph.D work email
- Valid
- Valid
Fatih M. Uckun, M.D., Ph.D personal email
Fatih M. Uckun, M.D., Ph.D phone numbers
Fatih M. Uckun, M.D., Ph.D, is an Active Member of the American Society for Clinical Investigation (ASCI), an honor society for physician-scientists, and an active member of several professional organizations, including ASCO, ASH and AACR. Dr. Uckun is a Principal Member of the Turkish Academy of Sciences/TUBA (a Member of the European Federation of Academies of Sciences and Humanities/ALLEA and Association of Academies and Societies of Sciences in Asia/AASSA). He earned his doctoral degrees at University of Heidelberg in Germany and completed his residency training in Pediatrics, fellowship training in Hematology/Oncology/Blood and Bone Marrow Stem Cell Transplantation, as well as postdoctoral research training in immunology at the University of Minnesota in the US. Dr. Uckun has more than 30 years of professional experience in developmental therapeutics and biopharmaceuticals in oncology/immuno-oncology as well as infectious diseases and immunology. Dr. Uckun worked 11 years as a Professor of Bone Marrow Transplantation, Therapeutic Radiology-Radiation Oncology, Pharmacology, and Pediatrics as well as Director of the Biotherapy Institute at the University of Minnesota, where he became the first recipient of the Endowed Hughes Chair in Biotherapy. He worked 6 years as a Professor and Head of Translational Research in Leukemia and Lymphoma of the CCBD and a Principal Investigator of the Stem Cell-Regenerative Medicine Initiative at the at the University of Southern California. He has held executive positions in multiple biotechnology companies and has extensive regulatory experience. He has published more than 500 peer-reviewed papers and he has authored numerous review articles and book chapters. He received numerous awards including the Stohlman Memorial Award of the Leukemia Society of America (now known as the Leukemia and Lymphoma Society/LLS), the highest honor given to a Leukemia Society Scholar. He has served as a member of several editorial boards and NIH grant review/special emphasis panels.In addition, Dr. Uckun has deep knowledge and 20+ years of experience in treatment of infectious diseases and their complications. He served as a Defense Advanced Research Projects Agency (DARPA) PI and directed a universal virus neutralizer program project as part of a countermeasures initiative against viruses that can be used as bioweapons. https://www.researchgate.net/profile/Fatih_Uckunhttps://loop.frontiersin.org/people/679873/biohttps://orcid.org/0000-0001-9334-183Xhttps://sciprofiles.com/profile/fatihuckun
Ares Pharmaceuticals, Llc
View- Employees:
- 3
-
Head Of Immuno-Oncology And Chief Medical And Chief Scientific Officer;Ares Pharmaceuticals, LlcBeverly Hills, Ca, Us -
Head Of Immuno-Oncology And Chief Medical/Chief Scientific Officer;Ares Pharmaceuticals, Llc Jul 2015 - PresentSt. Paul And Beverly Hills, Us -
Head Of Strategy For Clinical Development And Translational Hematology-OncologyAresmit Biomedical Computational Strategies (A.B.C.S) Jan 2017 - PresentMinneapolis, Minnesota, Us -
Chief Medical Officer/AdvisorOncotelic May 2022 - Feb 2023Agoura Hills, California, Ushttps://www.oncotelic.com/about-us/ -
Exec Vice President, Global Head Of Clinical And Medical Affairs; Chief Medical & Scientific OfficerReven Pharmaceuticals Jun 2020 - Mar 2022Westminster, Colorado, UsAs Executive Vice President, Clinical Affairs, Global Head of Clinical and Medical Affairs, and Chief Scientific Officer, Dr. Uckun’s responsibilities include providing medical-scientific leadership and direction for Reven’s pipeline of clinical development programs in sepsis, metabolic disorders, inflammatory disorders, including but not limited to non-alcoholic fatty liver disease and non-alcoholic steatohepatitis (NASH), iatrogenic organ toxicity, including chemotherapy-induced liver toxicity, and translational oncology as well as contributing to the strategy, direction and execution of the company's clinical development plans. Dr. Uckun will coordinate collaborations with academic centers and other biotech and pharmaceutical companies and provide day-to-day oversight for internal research, research and development, regulatory, safety as well as clinical operations teams. -
Consultant; Chief Clinical AdvisorAptevo Therapeutics Inc Mar 2021 - Dec 2021Seattle, Wa, UsAs a consultant to the Aptevo leadership, Dr. Uckun provides subject matter expertise in design of patient-centric clinical trials in acute leukemia patients. In collaboration with other leukemia experts at academic health centers in the US and Europe, he contributes to the design of clinical research protocols to evaluate Aptevo's bispecific antibodies as components of innovative multi-modality regimens that may improve the outcome of adult and pediatric acute leukemia patients. -
Vice President And Clinical Strategy Lead, Oncology-Hematology, Member Of Covid-19 Task ForceWorldwide Clinical Trials Jan 2020 - Jun 2020Research Triangle Park, Nc, Us -
Chief Medical OfficerOncotelic, Inc. Jan 2019 - Jan 2020http://oncotelic.com/management/
-
Chief Medical OfficerMateon Therapeutics Jan 2019 - Jan 2020South San Francisco, Ca, UsIn April 2019. Mateon Therapeutics, Inc. (OTCQB:MATN) and Oncotelic Inc. have completed their merger and created a new immuno-oncology company with a late-stage clinical asset against cancer and a promising product pipeline. In connection with the merger, Oncotelic, Inc. has become a wholly owned subsidiary of Mateon, with the former Oncotelic shareholders receiving a combination of common and preferred stock in Mateon representing approximately 85% of Mateon’s outstanding equity. Mateon’s prior stockholders retain approximately 15% of the outstanding equity. -
Executive Medical Director, Global Oncology & HematologySyneos Health (Previously Inc Research/Inventiv Health) Sep 2017 - Nov 2018Morrisville, Nc, UsFunction as a senior strategy advisor in Clinical Development, Global Oncology and Hematology with an emphasis on advanced solid tumors and relapsed or therapy-refractory hematologic malignanciesContribute to design of clinical path for small molecules as well as biologics with an emphasis on immuno-oncology drugs. Contribute to regulatory strategy for clinical development of multiple drug candidates, including targeted therapeutics, therapeutic vaccines, immuno-modulators, cytotoxic agents, immuno-oncology drugs. Contribute to biomarker identification and design of biomarker-guided clinical trialshttps://www.syneoshealth.com/ -
ProfessorUniversity Of Southern California Jul 2009 - Jun 2015Los Angeles, Ca, UsProfessor of Research Pediatrics, Department of Pediatrics at USC Keck School of MedicineMember, Developmental Therapeutics Program, Norris Comprehensive Cancer Center -
Principal Investigator; Usc Stem Cell Regenerative Medicine InitiativeUniversity Of Southern California Jul 2013 - May 2015Los Angeles, Ca, UsHematopoietic stem cell research -
Member, Norris Comprehensive Cancer CenterUniversity Of Southern California Jan 2010 - May 2015Los Angeles, Ca, UsTranslational cancer research -
Professor Research Pediatrics And Head, Translational Research In Leukemia And Lymphoma At The CccbdChildren'S Hospital Los Angeles Chla Jul 2009 - Jun 2015Los Angeles, Ca, UsProfessor Research PediatricsHead, Translational Research in Leukemia and Lymphoma -
Director, Research (Also Served As The Founding President/Ceo Of Its Spin-Off Biotech Companies)Drug Discovery Enterprises (Dba Parker Hughes Institute) 1997 - 2008A 501(c)3 research organization that was formed to discover new drug candidates against cancer. Spin off companies included Alexander Parker Corporation, Paradigm Pharmaceuticals, Jupiter Research.
-
President/CsoParadigm Pharmaceuticals Llc Oct 2002 - Feb 2007Coordinated target validation, portfolio prioritization, and drug discovery/development efforts in oncology and infectious diseases.
-
President/CsoAlexander Parker Corporation 1995 - 2000Coordinated the CRO function of the company for the Drug Discovery Enterprises, Inc(dba Parker Hughes Institute). Served as the lead FDA contact and IND Investigator-Sponsor for Phase 1, Phase 2 and randomized Phase 2 clinical trials of immuno-oncology products. Served as the lead contact for the Childrens Cancer Study Group for groupwide clinical testing of anti-CD19 immunoconjugates.Select references:Seibel NL, Sather H, Steinherz PG, De Laat C, Ettinger LJ, Freyer D, et al. Upfront treatment with B43 PAP immunotoxin in newly diagnosed children with higher risk ALL. Children's Cancer Group. Blood. 1961;2000;96:721a.Seibel NL, Krailo M, O'Neill K, Franklin J, Uckun F, Reaman GH. Phase I study of B43-PAP immunotoxin in combination with standard 4-drug induction for patients with CD19+ acute lymphoblastic leukemia (ALL) in relapse, a Children's Cancer Group Study. Pediatric Research. 1999;45:5. Abstract 195.
-
Director Of Biotherapy InstituteUniversity Of Minnesota 1995 - 1997Minneapolis And St. Paul, Minnesota, UsDirected translational biotherapy research on immunoconjugates, monoclonal antibodies, fusion toxins, and cytokine-drug conjugates. Reported to Provost of Academic Health Center and coordinated clinical and laboratory research efforts funded by multiple NIH grants. -
Full Professor (With Tenure)University Of Minnesota 1993 - 1997Minneapolis And St. Paul, Minnesota, UsConducted research and patient care and education -
Associate Professor (With Tenure)University Of Minnesota 1990 - 1992Minneapolis And St. Paul, Minnesota, UsConducted research and patient care and education -
Assistant ProfessorUniversity Of Minnesota 1986 - 1989Minneapolis And St. Paul, Minnesota, UsConducted research and patient care and education
Fatih M. Uckun, M.D., Ph.D Skills
Fatih M. Uckun, M.D., Ph.D Education Details
-
Heidelberg UniversityInternal Medicine -
University Of Minnesota Medical SchoolPediatrics Residency; Fellowship In Hematology/Oncology; Postdoctoral Fellowship In Immunology/Bmt
Frequently Asked Questions about Fatih M. Uckun, M.D., Ph.D
What company does Fatih M. Uckun, M.D., Ph.D work for?
Fatih M. Uckun, M.D., Ph.D works for Ares Pharmaceuticals, Llc
What is Fatih M. Uckun, M.D., Ph.D's role at the current company?
Fatih M. Uckun, M.D., Ph.D's current role is Head of Immuno-Oncology and Chief Medical and Chief Scientific Officer;.
What is Fatih M. Uckun, M.D., Ph.D's email address?
Fatih M. Uckun, M.D., Ph.D's email address is fm****@****ast.net
What is Fatih M. Uckun, M.D., Ph.D's direct phone number?
Fatih M. Uckun, M.D., Ph.D's direct phone number is +161281*****
What schools did Fatih M. Uckun, M.D., Ph.D attend?
Fatih M. Uckun, M.D., Ph.D attended Heidelberg University, University Of Minnesota Medical School.
What are some of Fatih M. Uckun, M.D., Ph.D's interests?
Fatih M. Uckun, M.D., Ph.D has interest in Children, Environment, Science And Technology, Disaster And Humanitarian Relief, Human Rights, Translational Research, Health.
What skills is Fatih M. Uckun, M.D., Ph.D known for?
Fatih M. Uckun, M.D., Ph.D has skills like Translational Research, Public Speaking, Cancer, Immunology, Clinical Research, Cancer Research, Cell, Cell Biology, Molecular Biology, Drug Discovery, Cell Culture, Biotechnology.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial